Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The price of Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed at $23.1 in the last session, up 2.08% from day before closing price of $22.63. In other words, the price has increased by $2.08 from its previous closing price. On the day, 1.83 million shares were traded. APLS stock price reached its highest trading level at $23.5 during the session, while it also had its lowest trading level at $22.79.
Ratios:
We take a closer look at APLS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 661.52. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.77. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.96.
On May 09, 2025, Raymond James Downgraded its rating to Outperform which previously was Strong Buy but kept the price unchanged to $52.
BofA Securities Downgraded its Buy to Neutral on May 09, 2025, while the target price for the stock was maintained at $23.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 19 ’25 when Dunlop A. Sinclair sold 31,092 shares for $22.95 per share. The transaction valued at 713,561 led to the insider holds 68,908 shares of the business.
Dunlop A. Sinclair bought 93,276 shares of APLS for $2,140,917 on Sep 19 ’25. On Sep 16 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $24.34 each. As a result, the insider received 121,700 and left with 118,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2917296896 and an Enterprise Value of 3012281856. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.87 while its Price-to-Book (P/B) ratio in mrq is 18.65. Its current Enterprise Value per Revenue stands at 3.992 whereas that against EBITDA is -16.0.
Stock Price History:
The Beta on a monthly basis for APLS is 0.68, which has changed by -0.19351387 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -6.14%, while the 200-Day Moving Average is calculated to be -2.76%.
Shares Statistics:
According to the various share statistics, APLS traded on average about 2.42M shares per day over the past 3-months and 2164550 shares per day over the past 10 days. A total of 126.19M shares are outstanding, with a floating share count of 104.36M. Insiders hold about 17.37% of the company’s shares, while institutions hold 101.09% stake in the company. Shares short for APLS as of 1757894400 were 21758081 with a Short Ratio of 9.00, compared to 1755216000 on 20273707. Therefore, it implies a Short% of Shares Outstanding of 21758081 and a Short% of Float of 22.690001000000002.
Earnings Estimates
As of right now, 13.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.34, with high estimates of $0.22 and low estimates of -$0.61.
Analysts are recommending an EPS of between $0.64 and -$2.29 for the fiscal current year, implying an average EPS of -$0.42. EPS for the following year is -$1.1, with 13.0 analysts recommending between $0.49 and -$2.24.
Revenue Estimates
According to 19 analysts,. The current quarter’s revenue is expected to be $371.95M. It ranges from a high estimate of $504.68M to a low estimate of $178M. As of. The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $196.83MFor the next quarter, 19 analysts are estimating revenue of $210.4M. There is a high estimate of $283M for the next quarter, whereas the lowest estimate is $182.1M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.04B, while the lowest revenue estimate was $705.4M, resulting in an average revenue estimate of $932.7M. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $904.72M in the next fiscal year. The high estimate is $1.02B and the low estimate is $757.8M.
